This brief article reviews a secondary analysis of the COMPASS (Cardiovascular Outcomes for People Using Anticoagulation Strategies) trial in patients with peripheral artery disease (PAD) treated with rivaroxaban and/or aspirin. The review suggests that treatment with rivaroxaban 2.5 mg twice daily with aspirin 100 mg daily may represent a new and effective treatment for PAD.

Read the Journal Scan